Pharma is slowing down: OPPI

Shahani said the sector seriously lacks domestic and foreign investments. ‘‘We need strong data protection, stringent intellectual property regime, price management and harmonious regulatory processes to attract foreign investors,’’ he said.

On reasons for the disappointing growth, Dr. Ajit V Dangi of OPPI said, ‘‘Generics are eroding valuation and there have been few new products over six months, causing dull performance.’’